Binding molecules for BCMA and CD3

US9340621B2 · kind B2 · utility

Assignees

• Boehringer Ingelheim International GmbH · DE
• AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

• Peter Kufer · Munich, DE
• Tobias Raum · Munich, DE
• Patrick Hoffmann · Munich, DE
• Roman Kischel · Munich, DE
• Ralf Lutterbuese · Munich, DE
• Doris Rau · Munich, DE
• Paul Adam · Wien, AT
• Eric Borges · Weitensfeld im Gurktal, AT
• Barbara Hebeis · Cambridge, GB
• Susanne Hipp · Ingelheim am Rhein, DE

Key dates

• Filing date: Nov 15, 2012
• Grant date: May 17, 2016
• Expiry date: Nov 15, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/43
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.